Infection with Leishmania causes significant morbidity and mortality worldwide. The type of Leishmania species infecting the host and the immune response generated by the host determines the spectrum of clinical disease that is seen. In particular, the pattern of cytokine production from T cells is critical for protection. At present there is no vaccine for Leishmania that is easy to administer, efficacious, and cost effective. Over the past year we developed new way to deliver vaccines using polymers and immune enhances that together lead to more robust immune responses but limits any toxicity.
|Darrah, Patricia A; Hegde, Sonia T; Patel, Dipti T et al. (2010) IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med 207:1421-33|
|Lindsay, Ross W B; Darrah, Patricia A; Quinn, Kylie M et al. (2010) CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling. J Immunol 185:1513-21|
|Lindenstrom, Thomas; Agger, Else Marie; Korsholm, Karen S et al. (2009) Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 182:8047-55|